eTheRNA immunotherapies

company

About

eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.

  • 51 - 100

Details

Last Funding Type
Grant
Last Funding Money Raised
€1M
Industries
Biotechnology,Health Care,Medical Device,Therapeutics
Founded date
Jan 1, 2013
Number Of Employee
51 - 100
Operating Status
Active

eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
€1M
eTheRNA immunotherapies has raised a total of €1M in funding over 2 rounds. Their latest funding was raised on Sep 25, 2017 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 25, 2017 Grant €1M 1 The Institute for the Promotion of Innovation by Science and Technology in Flanders Detail

Investments

Number of Investments
Number of Lead Investments
2
0
eTheRNA immunotherapies has made 2 investments. Their most recent investment was on Sep 16, 2013, when Armory Technologies, Inc. raised $600K.
Date Company Name
Round Money Raised Industry Lead Investor
Seed $600K Bitcoin
Jan 7, 2013 BitPay
Seed $510K Bitcoin

Investors

Number of Lead Investors
Number of Investors
1
1
eTheRNA immunotherapies is funded by 1 investors. The Institute for the Promotion of Innovation by Science and Technology in Flanders are the most recent investors.
Investor Name Lead Investor Funding Round
The Institute for the Promotion of Innovation by Science and Technology in Flanders Yes Grant